MPD: Phenotype measures mapped to MP:0002723, abnormal immune serum protein physiology

Phenotype measures associated with ontology term
MP:0002723 'abnormal immune serum protein physiology'

This list includes measures mapped MP:0002723 AND its ontology descendants. Alternatively, you can show measures mapped to MP:0002723 only.

This MP term has been mapped to these MPD phenotype measurements to help users find relevant data. It should be noted that MPD measurements typically have a mixture of high-end, low-end and "normal" readings.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Auwerx1:195	Auwerx1	cell signaling molecule detection	high-fat diet	blood interferon gamma (INF gamma) amount [pg/mL] inf_gamma 111374 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:197	Auwerx1	cell signaling molecule detection	high-fat diet	blood interleukin-18 (IL-18) amount [pg/mL] il_18 111376 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:199	Auwerx1	cell signaling molecule detection	high-fat diet	blood interleukin-6 (IL-6) amount [pg/mL] il_6 111378 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:201	Auwerx1	cell signaling molecule detection	high-fat diet	blood interleukin-10 (IL-10) amount [pg/mL] il_10 111380 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:203	Auwerx1	cell signaling molecule detection	high-fat diet	blood interleukin-15 (IL-15) amount [pg/mL] il_15 111382 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:205	Auwerx1	cell signaling molecule detection	high-fat diet	blood monocyte chemoattractant protein 1 (MCP1) amount [pg/mL] mcp1 111384 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:207	Auwerx1	cell signaling molecule detection	high-fat diet	blood macrophage inflammatory protein 1 alpha subunit (MIP1 alpha) amount [pg/mL] mip1_alpha 111386 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:209	Auwerx1	cell signaling molecule detection	high-fat diet	blood macrophage inflammatory protein 1 beta subunit (MIP1 beta) amount [pg/mL] mip1_beta 111388 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:211	Auwerx1	cell signaling molecule detection	high-fat diet	blood regulated on activation, normal T cell expressed and secreted (RANTES) protein amount [pg/mL] rantes 111390 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx1:213	Auwerx1	cell signaling molecule detection	high-fat diet	blood tumor necrosis factor alpha (TNF alpha) amount [pg/mL] tnf_alpha 111392 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Cowell1:1	Cowell1	hormone quantification	Staphylococcus aureus	fold-change in serum IL-6 levels 24h post-infection compared to controls [ratio] IL6 49001	inbred	13	f	8wks	N=3	2012

Donahue7:1	Donahue7	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 41601	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue7:2	Donahue7	immunoglobulin quantification	(none)	immunoglobulin G (plasma IgG) [µg/mL] IgG 41602	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue7:3	Donahue7	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 41603	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue8:1	Donahue8	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 41701	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Donahue8:2	Donahue8	immunoglobulin quantification	(none)	immunoglobulin G (plasma IgG) [µg/mL] IgG 41702	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Donahue8:3	Donahue8	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 41703	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Eumorphia7:1	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin M (serum IgM) [µg/mL] IgM 29601	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:2	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G3 (serum IgG3) [µg/mL] IgG3 29602	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:3	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G1 (serum IgG1) [µg/mL] IgG1 29603	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:4	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G2b (serum IgG2b) [µg/mL] IgG2b 29604	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:5	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G2a (serum IgG2a) [µg/mL] IgG2a 29605	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:6	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin A (serum IgA) [µg/mL] IgA 29606	inbred	6	both	9-12wks	N=5	2008

Farmer1:29	Farmer1	hormone quantification	(none)	lgG2a antibodies against escherichia coli membrane antigens [ng/ml] IgG2aantiECM 11329	QTL population		both	6wks	N=206	2001

Farmer1:30	Farmer1	hormone quantification	(none)	levels of total lgG reactivity against escherichia coli membrane (ECM) antigens [ng/ml] IgGantiECM 11330	QTL population		both	6wks	N=206	2001

Farmer1:31	Farmer1	hormone quantification	(none)	secretory IgA in collected blood [ng/ml] IgA 11331	QTL population		both	6wks	N=206	2001

Farmer1:32	Farmer1	hormone quantification	(none)	levels of IgA secreted in feces [ng/ml] IgAfeces 11332	QTL population		both	6wks	N=206	2001

Farmer1:33	Farmer1	immune cell quantification	(none)	percentage of Interleukin 12 in collected blood [%] IL12 11333	QTL population		both	6wks	N=206	2001

GMC20:2	GMC20	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 56902 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:4	GMC20	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 56904 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=5	2018

GMC20:6	GMC20	immunoglobulin quantification	(none)	immunoglobulin G1 (plasma IgG1) [µg/mL] IgG1 56906 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=4	2018

GMC20:8	GMC20	immunoglobulin quantification	(none)	immunoglobulin G2a (plasma IgG2a) [µg/mL] IgG2a 56908 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:10	GMC20	immunoglobulin quantification	(none)	immunoglobulin G2b (plasma IgG2b) [µg/mL] IgG2b 56910 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=4	2018

GMC20:12	GMC20	immunoglobulin quantification	(none)	immunoglobulin G3 (plasma IgG3) [µg/mL] IgG3 56912 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:14	GMC20	immunoglobulin quantification	(none)	immunoglobulin E (plasma IgE) [ng/mL] IgE 56914 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

Graham1:61	Graham1	immunoglobulin quantification	West Nile virus	virus-specific IgM in serum, post infection [ng/mL] WNV_IgM 63361 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:76	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in brain, fold change compared to matched control, post infection Ifnb1_brain 63376 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:79	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in kidney, fold change compared to matched control, post infection Ifnb1_kidney 63379 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:83	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in spleen, fold change compared to matched control, post infection Ifnb1_spleen 63383 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham3:49	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are IL-17+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD8_pos_IL17_pos 113840	CC RIX	102	m	8-10wks	N=4	2021

Graham3:50	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are IFNg+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD8_pos_IGNg_pos 113841	CC RIX	102	m	8-10wks	N=4	2021

Graham3:52	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are IL-17+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_IL17_pos 113843	CC RIX	102	m	8-10wks	N=4	2021

Graham3:53	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are IFNg+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_IFNg_pos 113844	CC RIX	102	m	8-10wks	N=4	2021

Noll1:26	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin M (serum IgM) area under curve (AUC) post-infection [AUC] IgM 112602 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=4	2020

Noll1:31	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin G1 (serum IgG1) area under curve (AUC) post-infection [AUC] IgG1 112607 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=4	2020

Noll1:36	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin G2a plus G2c (serum IgG2a pooled with IgG2c) area under curve (AUC) post-infection [AUC] IgG2ac 112612 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=4	2020

Noll1:41	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin G2b (serum IgG2b) area under curve (AUC) post-infection [AUC] IgG2b 112617 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=3	2020

Noll1:46	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	immunoglobulin G3 (serum IgG3) area under curve (AUC) post-infection [AUC] IgG3 112622 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	46	f	8-12 wks	N=4	2020

Noll1:51	Noll1	immunoglobulin quantification	influenza A (H1N1) virus	total immunoglobulin G (serum IgG) area under curve (AUC) post-infection [AUC] Total_IgG 112627 post-infection: day 7 day 10 day 15 day 29 day 45	CC RIX	44	f	8-12 wks	N=3	2020

Peters1:25	Peters1	coagulation test	(none)	fibrinogen [mg/dL] Fib 6225	inbred w/CC7	43	both	10wks	N=10	2001

Svenson3:43	Svenson3	coagulation test	(none)	blood fibrinogen [mg/dL] Fib 27343	B6.PWD consomic w/par	23	both	6wks	N=8	2006

Zaytseva1:1	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 1, core fucose with 1 GlcNAc antenna (relative abundance) [%] gp1 110006	CC	111	both	4-140wks	N=3	2018

Zaytseva1:2	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 2, composition not determined (relative abundance) [%] gp2 110007	CC	111	both	4-140wks	N=3	2018

Zaytseva1:3	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 3, composition not determined (relative abundance) [%] gp3 110008	CC	111	both	4-140wks	N=3	2018

Zaytseva1:4	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 4, core fucose with 2 GlcNAc antennae (relative abundance) [%] gp4 110009	CC	111	both	4-140wks	N=3	2018

Zaytseva1:5	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 5, composition not determined (relative abundance) [%] gp5 110010	CC	111	both	4-140wks	N=3	2018

Zaytseva1:6	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 6, core fucose with bisecting GlcNAc and 2 GlcNAc antennae (relative abundance) [%] gp6 110011	CC	111	both	4-140wks	N=3	2018

Zaytseva1:7	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 7, composition not determined (relative abundance) [%] gp7 110012	CC	111	both	4-140wks	N=3	2018

Zaytseva1:8	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 8, core fucose with 2 GlcNAc antennae, 1 galactose linked to alpha1,6-linked core mannose (relative abundance) [%] gp8 110013	CC	111	both	4-140wks	N=3	2018

Zaytseva1:9	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 9, core fucose with 2 GlcNAc antennae, 1 galactose linked to alpha1,3-linked core mannose (relative abundance) [%] gp9 110014	CC	111	both	4-140wks	N=3	2018

Zaytseva1:10	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 10, core fucose with bisecting GlcNAc and 2 GlcNAc antennae, 1 galactose linked to alpha1,6-linked core mannose (relative abundance) [%] gp10 110015	CC	111	both	4-140wks	N=3	2018

Zaytseva1:11	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 11, composition not determined (relative abundance) [%] gp11 110016	CC	111	both	4-140wks	N=3	2018

Zaytseva1:12	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 12, composition not determined (relative abundance) [%] gp12 110017	CC	111	both	4-140wks	N=3	2018

Zaytseva1:13	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 13, composition not determined (relative abundance) [%] gp13 110018	CC	111	both	4-140wks	N=3	2018

Zaytseva1:14	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 14, core fucose with 2 GlcNAc antennae, 2 galactoses (relative abundance) [%] gp14 110019	CC	111	both	4-140wks	N=3	2018

Zaytseva1:15	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 15, composition not determined (relative abundance) [%] gp15 110020	CC	111	both	4-140wks	N=3	2018

Zaytseva1:16	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 16, composition not determined (relative abundance) [%] gp16 110021	CC	111	both	4-140wks	N=3	2018

Zaytseva1:17	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 17a, core fucose with 2 GlcNAc antennae, 1 galactose linked to alpha1,6-linked core mannose, 1 sialic acid (relative abundance) [%] gp17a 110022	CC	111	both	4-140wks	N=3	2018

Zaytseva1:18	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 17b, core fucose with 2 GlcNAc antennae, 1 galactose linked to alpha1,3-linked core mannose, 1 sialic acid (relative abundance) [%] gp17b 110023	CC	111	both	4-140wks	N=3	2018

Zaytseva1:19	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 18, composition not determined (relative abundance) [%] gp18 110024	CC	111	both	4-140wks	N=3	2018

Zaytseva1:20	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 19, composition not determined (relative abundance) [%] gp19 110025	CC	111	both	4-140wks	N=3	2018

Zaytseva1:21	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 20, core fucose with 2 GlcNAc antennae, 2 galactoses, 1 sialic acid (relative abundance) [%] gp20 110026	CC	111	both	4-140wks	N=3	2018

Zaytseva1:22	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 21, composition not determined (relative abundance) [%] gp21 110027	CC	111	both	4-140wks	N=3	2018

Zaytseva1:23	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 22, composition not determined (relative abundance) [%] gp22 110028	CC	111	both	4-140wks	N=3	2018

Zaytseva1:24	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 23, core fucose with 2 GlcNAc antennae, 3 galactoses, 1 sialic acid (relative abundance) [%] gp23 110029	CC	111	both	4-140wks	N=3	2018

Zaytseva1:25	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 24, composition not determined (relative abundance) [%] gp24 110030	CC	111	both	4-140wks	N=3	2018

Zaytseva1:26	Zaytseva1	glycosylation profile	(none)	IgG glycan peak 25, core fucose with 2 GlcNAc antennae, 2 galactoses, 2 sialic acids (relative abundance) [%] gp25 110031	CC	111	both	4-140wks	N=3	2018

Zaytseva2:1	Zaytseva2	glycosylation profile	(none)	IgG1 with bisected N-acetylglucosamine N-glycan structures (relative abundance) [%] mIgG1_B 110032	CC	94	both	20-117wks	N=2	2018

Zaytseva2:2	Zaytseva2	glycosylation profile	(none)	IgG1 with galactosylated N-glycan structures (relative abundance) [%] mIgG1_G 110033	CC	94	both	20-117wks	N=2	2018

Zaytseva2:3	Zaytseva2	glycosylation profile	(none)	IgG1 with agalactosylated N-glycan structures (relative abundance) [%] mIgG1_G0 110034	CC	94	both	20-117wks	N=2	2018

Zaytseva2:4	Zaytseva2	glycosylation profile	(none)	IgG1 with monogalactosylated N-glycan structures (relative abundance) [%] mIgG1_G1 110035	CC	94	both	20-117wks	N=2	2018

Zaytseva2:5	Zaytseva2	glycosylation profile	(none)	IgG1 with digalactosylated N-glycan structures (relative abundance) [%] mIgG1_G2 110036	CC	94	both	20-117wks	N=2	2018

Zaytseva2:6	Zaytseva2	glycosylation profile	(none)	IgG1 with sialylated N-glycan structures (relative abundance) [%] mIgG1_S 110037	CC	94	both	20-117wks	N=2	2018

Zaytseva2:7	Zaytseva2	glycosylation profile	(none)	IgG1 with monosialylated N-glycan structures (relative abundance) [%] mIgG1_S1 110038	CC	94	both	20-117wks	N=2	2018

Zaytseva2:8	Zaytseva2	glycosylation profile	(none)	IgG1 with disialylated N-glycan structures (relative abundance) [%] mIgG1_S2 110039	CC	94	both	20-117wks	N=2	2018

Zaytseva2:9	Zaytseva2	glycosylation profile	(none)	IgG1 with alpha1,3-linked galactose residue N-glycan structures (relative abundance) [%] mIgG1_aGal 110040	CC	94	both	20-117wks	N=2	2018

Zaytseva2:10	Zaytseva2	glycosylation profile	(none)	IgG2 with bisected N-acetylglucosamine N-glycan structures (relative abundance) [%] mIgG2_B 110041	CC	94	both	20-117wks	N=2	2018

Zaytseva2:11	Zaytseva2	glycosylation profile	(none)	IgG2 with galactosylated N-glycan structures (relative abundance) [%] mIgG2_G 110042	CC	94	both	20-117wks	N=2	2018

Zaytseva2:12	Zaytseva2	glycosylation profile	(none)	IgG2 with agalactosylated N-glycan structures (relative abundance) [%] mIgG2_G0 110043	CC	94	both	20-117wks	N=2	2018

Zaytseva2:13	Zaytseva2	glycosylation profile	(none)	IgG2 with monogalactosylated N-glycan structures (relative abundance) [%] mIgG2_G1 110044	CC	94	both	20-117wks	N=2	2018

Zaytseva2:14	Zaytseva2	glycosylation profile	(none)	IgG2 with digalactosylated N-glycan structures (relative abundance) [%] mIgG2_G2 110045	CC	94	both	20-117wks	N=2	2018

Zaytseva2:15	Zaytseva2	glycosylation profile	(none)	IgG2 with sialylated N-glycan structures (relative abundance) [%] mIgG2_S 110046	CC	94	both	20-117wks	N=2	2018

Zaytseva2:16	Zaytseva2	glycosylation profile	(none)	IgG2 with monosialylated N-glycan structures (relative abundance) [%] mIgG2_S1 110047	CC	94	both	20-117wks	N=2	2018

Zaytseva2:17	Zaytseva2	glycosylation profile	(none)	IgG2 with disialylated N-glycan structures (relative abundance) [%] mIgG2_S2 110048	CC	94	both	20-117wks	N=2	2018

Zaytseva2:18	Zaytseva2	glycosylation profile	(none)	IgG2 with alpha1,3-linked galactose residue N-glycan structures (relative abundance) [%] mIgG2_aGal 110049	CC	94	both	20-117wks	N=2	2018

Zaytseva2:19	Zaytseva2	glycosylation profile	(none)	IgG3 with bisected N-acetylglucosamine N-glycan structures (relative abundance) [%] mIgG3_B 110050	CC	95	both	20-117wks	N=2	2018

Zaytseva2:20	Zaytseva2	glycosylation profile	(none)	IgG3 with galactosylated N-glycan structures (relative abundance) [%] mIgG3_G 110051	CC	95	both	20-117wks	N=2	2018

Zaytseva2:21	Zaytseva2	glycosylation profile	(none)	IgG3 with agalactosylated N-glycan structures (relative abundance) [%] mIgG3_G0 110052	CC	95	both	20-117wks	N=2	2018

Zaytseva2:22	Zaytseva2	glycosylation profile	(none)	IgG3 with monogalactosylated N-glycan structures (relative abundance) [%] mIgG3_G1 110053	CC	95	both	20-117wks	N=2	2018

Zaytseva2:23	Zaytseva2	glycosylation profile	(none)	IgG3 with digalactosylated N-glycan structures (relative abundance) [%] mIgG3_G2 110054	CC	95	both	20-117wks	N=2	2018

Zaytseva2:24	Zaytseva2	glycosylation profile	(none)	IgG3 with sialylated N-glycan structures (relative abundance) [%] mIgG3_S 110055	CC	95	both	20-117wks	N=2	2018

Zaytseva2:25	Zaytseva2	glycosylation profile	(none)	IgG3 with monosialylated N-glycan structures (relative abundance) [%] mIgG3_S1 110056	CC	95	both	20-117wks	N=2	2018

Zaytseva2:26	Zaytseva2	glycosylation profile	(none)	IgG3 with disialylated N-glycan structures (relative abundance) [%] mIgG3_S2 110057	CC	95	both	20-117wks	N=2	2018

Zaytseva2:27	Zaytseva2	glycosylation profile	(none)	IgG3 with alpha1,3-linked galactose residue N-glycan structures (relative abundance) [%] mIgG3_aGal 110058	CC	95	both	20-117wks	N=2	2018

Filter Table Results